2007;83 5 Suppl: S27 S86. 1110. Ferraris VA, Ferraris SP, Moliterno DJ, et al. The Society of Thoracic Surgeons practice guideline series: aspirin and other antiplatelet agents during operative coronary revascularization (executive summary). Ann Thorac Surg. 2005;79:1454 61. 1111. Henry D, Carless P, Fergusson D, et al. The safety of aprotinin and lysine-derived antifibrinolytic drugs in cardiac surgery: a meta-analy- sis. CMAJ. 2009;180:183 93. 1112. Sowade O, Warnke H, Scigalla P, et al. Avoidance of allogeneic blood transfusions by treatment with epoetin beta (recombinant human eryth- ropoietin) in patients undergoing open-heart surgery. Blood. 1997;89: 411 8. 1113. D Ambra MN, Gray RJ, Hillman R, et al. Effect of recombinant human erythropoietin on transfusion risk in coronary bypass patients. Ann Thorac Surg. 1997;64:1686 93. 1114. Podesta A, Carmagnini E, Parodi E, et al. Elective coronary and valve surgery without blood transfusion in patients treated with recombinant human erythropoietin (epoetin-alpha). Minerva Cardioangiol. 2000;48: 341 7. 1115. Schmoeckel M, Nollert G, Mempel M, et al. Effects of recombinant human erythropoietin on autologous blood donation before open heart surgery. Thorac Cardiovasc Surg. 1993;41:364 8. 1116. Kulier AH, Gombotz H, Fuchs G, et al. Subcutaneous recombinant human erythropoietin and autologous blood donation before coronary artery bypass surgery. Anesth Analg. 1993;76:102 6. 1117. Hayashi J, Kumon K, Takanashi S, et al. Subcutaneous administration of recombinant human erythropoietin before cardiac surgery: a double- blind, multicenter trial in Japan. Transfusion. 1994;34:142 6. 1118. Walpoth B, Galliker B, Spirig P, et al. Use of epoetin alfa in autologous blood donation programs for patients scheduled for elective cardiac surgery. Semin Hematol. 1996;33:75 6. 1119. Watanabe Y, Fuse K, Naruse Y, et al. Subcutaneous use of erythro- poietin in heart surgery. Ann Thorac Surg. 1992;54:479 83. 1120. Kiyama H, Ohshima N, Imazeki T, et al. 